Taylor Jensen, Ph.D. serves as Vice President, Head of Oncology Science at Labcorp where he leads research and development, bioinformatics, software development, and manufacturing for precision oncology laboratory offerings and products.
After studying in the field of cancer epigenetics, Dr. Jensen joined Sequenom in 2009 and was a key contributor of the team that developed and launched the first commercially available, noninvasive, prenatal test based on circulating cell-free DNA (cfDNA) in the U.S.
Subsequently, Dr. Jensen was involved in numerous assay development efforts focused on the identification and detection of genomic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics.
Since the acquisition of Sequenom by Labcorp in 2016, Dr. Jensen has held several positions focused on driving the advancement of innovative oncology assays, including the development and validation of laboratory developed tests (LDTs) pursuant to CAP/CLIA and New York State requirements, and the development an in vitro diagnostic (IVD) test, the first FDA-authorized kitted liquid biopsy solution. In addition to these accomplishments, he had general management responsibilities for the companion diagnostic development organization, including oversight of the regulatory affairs team that led to the approval of Labcorp’s first CDx assay that is used to identify patients eligible for a gene therapy.
Overall, Dr. Jensen’s work has primarily focused on pioneering novel technologies and assays with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including the American Association for Cancer Research and the American Society of Clinical Oncology, has contributed to multiple awarded patents, and has authored or co-authored more than 40 publications in peer reviewed scientific journals. He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.